Y-Intercept (HK)
RCEL icon

Y-Intercept (HK)’s Avita Medical RCEL Stock Holding History

Y-Intercept (HK)’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$143K Buy
+12,203
New +$96.7K ﹤0.01% 1500

Other funds holding RCEL

AHL
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
HCA
Harpswell Capital Advisors Yarmouth, Maine $152M AUM 8.39% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s RCEL Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Avita Medical (RCEL) in Q3 2026: 12,203 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #1500 among its holdings.

8 funds tracked by Wall St. Rank hold RCEL as of Q3 2026.

  • Y-Intercept (HK) held 12,203 shares of Avita Medical worth $143K as of Q3 2026.
  • Avita Medical was a new Y-Intercept (HK) position in Q3 2026.
  • Avita Medical made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1500 holding.
  • 8 funds tracked by Wall St. Rank held Avita Medical as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.